Physiomics Advances Precision Oncology Dosing
Company Announcements

Physiomics Advances Precision Oncology Dosing

Physiomics (GB:PYC) has released an update.

Physiomics PLC has partnered with DoseMe to integrate its personalized dosing software into the DoseMeRx platform, enhancing precision in chemotherapy and GCSF dosing for cancer treatments. This collaboration builds on past successful grants and aims to provide decision support for clinicians, with plans to make the software available for research use in the second half of 2024. Physiomics is also exploring ways to simplify blood sampling for patients, considering options like new diagnostic devices and possible business structure changes to focus on this software development.

For further insights into GB:PYC stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskPhysiomics CEO Boosts Shareholding, Signals Confidence
TipRanks UK Auto-Generated NewsdeskPhysiomics CEO Increases Stake in Company
TipRanks UK Auto-Generated NewsdeskPhysiomics Strengthens Leadership with New Senior Appointment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App